Ros Cutts

1.7k total citations
15 papers, 431 citations indexed

About

Ros Cutts is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ros Cutts has authored 15 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cancer Research, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Ros Cutts's work include Cancer Genomics and Diagnostics (9 papers), Advanced Breast Cancer Therapies (5 papers) and Fibroblast Growth Factor Research (3 papers). Ros Cutts is often cited by papers focused on Cancer Genomics and Diagnostics (9 papers), Advanced Breast Cancer Therapies (5 papers) and Fibroblast Growth Factor Research (3 papers). Ros Cutts collaborates with scholars based in United Kingdom, United States and Australia. Ros Cutts's co-authors include Nicholas C. Turner, María Teresa Herrera-Abreu, Uzma Asghar, Irina S. Babina, Alex Pearson, Matthew Beaney, Chris Bakal, Deepak Sampath, Lisa Crocker and Jennifer M. Giltnane and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Ros Cutts

14 papers receiving 430 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ros Cutts United Kingdom 9 296 268 209 116 47 15 431
J-Y Pierga France 11 376 1.3× 135 0.5× 183 0.9× 113 1.0× 51 1.1× 53 479
Dario Romagnoli Italy 10 254 0.9× 271 1.0× 205 1.0× 200 1.7× 88 1.9× 23 467
Núria Chic Spain 9 322 1.1× 252 0.9× 211 1.0× 173 1.5× 70 1.5× 53 502
Jorge E. Buendia-Buendia United States 5 238 0.8× 157 0.6× 186 0.9× 265 2.3× 23 0.5× 9 512
Esther Sanfeliu Spain 5 131 0.4× 157 0.6× 106 0.5× 149 1.3× 46 1.0× 24 338
Hyatt Balke‐Want Germany 7 323 1.1× 307 1.1× 90 0.4× 222 1.9× 17 0.4× 14 464
Celina Sanchez Rivers Australia 4 226 0.8× 199 0.7× 141 0.7× 280 2.4× 15 0.3× 4 488
Miklós Dióssy Denmark 10 274 0.9× 137 0.5× 127 0.6× 237 2.0× 20 0.4× 11 400
Lingzhu Wen China 10 181 0.6× 96 0.4× 165 0.8× 153 1.3× 21 0.4× 24 341
Lisa Flaum United States 11 370 1.3× 207 0.8× 299 1.4× 127 1.1× 20 0.4× 32 535

Countries citing papers authored by Ros Cutts

Since Specialization
Citations

This map shows the geographic impact of Ros Cutts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ros Cutts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ros Cutts more than expected).

Fields of papers citing papers by Ros Cutts

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ros Cutts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ros Cutts. The network helps show where Ros Cutts may publish in the future.

Co-authorship network of co-authors of Ros Cutts

This figure shows the co-authorship network connecting the top 25 collaborators of Ros Cutts. A scholar is included among the top collaborators of Ros Cutts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ros Cutts. Ros Cutts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Cutts, Ros, Sarah Hrebien, Aditi Gulati, et al.. (2024). Discriminating subtypes in advanced breast cancer with ctDNA methylation profiling.. Journal of Clinical Oncology. 42(16_suppl). 1013–1013.
2.
García-Murillas, Isaac, Ros Cutts, Charles W. Abbott, et al.. (2024). Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1010–1010. 8 indexed citations
3.
Gunu, Richard, Allison Jones, Adeola Olaitan, et al.. (2023). Circulating HPV DNA as a Biomarker for Pre-Invasive and Early Invasive Cervical Cancer: A Feasibility Study. Cancers. 15(9). 2590–2590. 7 indexed citations
4.
Pascual, Javier, Miguel Martín, Paula Proszek, et al.. (2022). Baseline and longitudinal ctDNA biomarkers in GEICAM/2013-02 (PEARL) trial cohort 2 comparing palbociclib and fulvestrant (PAL + FUL) versus capecitabine (CAPE).. Journal of Clinical Oncology. 40(16_suppl). 1019–1019. 1 indexed citations
5.
Kingston, Belinda, Alex Pearson, María Teresa Herrera-Abreu, et al.. (2022). ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study.. Journal of Clinical Oncology. 40(16_suppl). 1009–1009. 5 indexed citations
6.
Hrebien, Sarah, Valentina Citi, Isaac García-Murillas, et al.. (2019). Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Annals of Oncology. 30(6). 945–952. 100 indexed citations
7.
O’Leary, Ben, Ros Cutts, Xin Huang, et al.. (2019). Genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial.. Journal of Clinical Oncology. 37(15_suppl). 1010–1010. 10 indexed citations
8.
López‐Knowles, Elena, Alex Pearson, Eugene F. Schuster, et al.. (2018). Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. British Journal of Cancer. 120(2). 247–255. 12 indexed citations
9.
Turner, Nicholas C., Ben O’Leary, Ros Cutts, et al.. (2018). Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant.. Journal of Clinical Oncology. 36(15_suppl). 1001–1001. 13 indexed citations
10.
Asghar, Uzma, Alexis R. Barr, Ros Cutts, et al.. (2017). Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. Clinical Cancer Research. 23(18). 5561–5572. 203 indexed citations
11.
Smyth, Elizabeth, Nicholas C. Turner, Alex Pearson, et al.. (2016). Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.. Journal of Clinical Oncology. 34(4_suppl). 154–154. 15 indexed citations
12.
Pender, Alexandra, Sareena Rana, Isaac García-Murillas, et al.. (2016). Simultaneous EGFR mutation detection and copy number assessment in circulating tumour DNA (ctDNA) to inform molecular methods of therapy resistance and plasma ctDNA content in lung adenocarcinoma.. Journal of Clinical Oncology. 34(15_suppl). e23027–e23027. 1 indexed citations
13.
Smyth, Elizabeth, Nicholas C. Turner, Clare Peckitt, et al.. (2015). Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.. Journal of Clinical Oncology. 33(15_suppl). 2508–2508. 37 indexed citations
14.
Asghar, Uzma, María Teresa Herrera-Abreu, Ros Cutts, et al.. (2015). Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition.. Journal of Clinical Oncology. 33(15_suppl). 11098–11098. 18 indexed citations
15.
Babina, Irina S., Alex Pearson, Ros Cutts, et al.. (2015). Abstract C37: Molecular determinants of sensitivity and resistance to FGFR inhibition in FGFR2-amplified gastric cancer. Molecular Cancer Therapeutics. 14(12_Supplement_2). C37–C37. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J-Y Pierga Breakdown of academic impact, for papers by Dario Romagnoli Breakdown of academic impact, for papers by Núria Chic Breakdown of academic impact, for papers by Jorge E. Buendia-Buendia Breakdown of academic impact, for papers by Esther Sanfeliu Breakdown of academic impact, for papers by Hyatt Balke‐Want Breakdown of academic impact, for papers by Celina Sanchez Rivers Breakdown of academic impact, for papers by Miklós Dióssy Breakdown of academic impact, for papers by Lingzhu Wen Breakdown of academic impact, for papers by Lisa Flaum
Rankless by CCL
2026